Introduction: Cancer cervix is a common genital cancer. Human papillomavirus is the main cause of cervical cancer because of the strong association of certain HPV genotypes and the development of cervical cancer and its precursor lesions, cervical intraepithelial neoplasia CIN 2 or CIN3.
INTRODUCTION
Cancer cervix is the most common gynecological malignancy and third most common malignancy in women after breast and colorectal cancers. It constitutes about 12% of all malignancies in women. Highest incidence of carcinoma is reported in Cali, Colombia (52/100,000) and lowest in Kuwait (3/100,000). 1 Early detection of pre-invasive disease and treatment of CIN has the potential to improve the outcome of patients. Invasive cancer of cervix is considered to be a preventable condition, since it is associated with a long pre-invasive stage (CIN), making it amenable to screening and treatment.
Cervical cancer, which develops from cervical intraepithelial neoplasia (CIN), is an important cause of death in women worldwide. The introduction of Pap smear test decades ago has reduced the incidence of cervical cancer in most developed and some developing countries as well. Although Pap test has the merits of being convenient, reasonably specific and inexpensive, concern about the low sensitivity of the Pap smear test in detecting cervical cancer lesions has prompted a search for newer methods to either supplement or replace it. A low sensitivity of Pap test would put women at risk to develop invasive cervical cancer. In view of importance of human papillomavirus (HPV) in the etiology of cervical cancer, HPV DNA testing which allow women to be classified as high-risk HPV positive or negative could be used as an adjunct to Pap test. Total detection rate of Cervical Intraepithelial Neoplasia in total 180 women was 27 (15%), total Incidence of CIN I was 7.22%, CIN II was 3.89%, CIN III was 3.33% and SCC was 0.56% in total 180 women. it showed that the incidence of higher grades of neoplasia was found to increase as age increases. Majority (33.89%) of the women attending Gynecology and Oncosurgery presented with complaints of white discharge per vaginum followed by 34 % of the population who had come for routine screening. Women who had their routine screen, CIN I was detected in 4 women, 3 women had CIN III and 2 of them had CIN II. Hence total incidence of neoplasia was 9 (14.75 %). 11 (14.28 %) women presenting with white vaginal discharge were detected with neoplasia. Among 8 women having complaints of postmenopausal bleeding 2 (25 %) were detected of neoplasia. One had SCC and 1 had CIN III. Hence, postmenopausal bleeding is one of the risk factors for cervical neoplasia/ squamous cell carcinoma. In the study, benign cellular changes (65%) were the highest reported in the cytology, followed by ASCUS (13.33%). Only 1 (0.56%) LSIL was reported. 6.11% women had HSIL. 15 % had normal smear. No SCC/AGUS was reported in the cytology. 
DISCUSSION
The management and the prevention of cervical cancer should change definitely with DNA testing for high risk HPV, which is more sensitive than cytology. Infection of cervix with HPV is necessary to cause cervical neoplasia and cervical cancer. Although 80 % of HPV infection clear within 2 years and does not cause cervical neoplasia, persistent infection with HPV is required for the development of cervical dysplasia and invasive cervical cancer. 1 The mean age of women in various studies were also compared. The mean age of the participating women in the present study was 41.48. In the study conducted by Yuonne N Flores et al, 3 the mean age resulted as 39.5 which are in near proximity with the result of the present study.
Multiparous patients stand a statistically significant risk of acquiring genital HPV infection compared to their non-parous counterparts.
In our study, 97.22% women had single sexual partner and 2.78% had multiple sexual partners and only one was the smoker. Her cervical biopsy report was CIN III. This can be accounted for good number of patients being referred for HPV testing in view of abnormal Pap smear.
HPV testing has demonstrated the increased sensitivity for detection of cervical neoplasia. Greater sensitivity associated with greater negative predictive value. High negative predictive value implies it is the best primary screening test. 7 As there is close association between HPV infection and invasive cancer, identification of high-risk type could be an important tool for screening of carcinoma cervix. Primary screening procedure if not reliable and feasible for developing country, HPV DNA can strengthen the result. 8 Hence, HPV being the most important causative factor for carcinoma cervix, its detection is an important tool for screening of carcinoma cervix. HPV DNA analysis for high risk group of the virus is more sensitive when compared to Pap smear as a screening method.
World Health Organization and the European research Organization on Genital Infection and Neoplasia in the year 2000 mentioned that HPV testing showed 95-100% sensitivity for high grade cancer precursors compared with 40-85 % for traditional cervical cytology (Pap test). This fact strongly suggests HPV testing should be adopted as the primary screening method for women over age 30.
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CONCLUSIONS
The advent of HPV testing has opened the doors for more accurate cervical cancer surveillance strategies than Pap smear. Randomized controlled trials of HPV testing alone have demonstrated that women compared with standard cytologic screening, HPV testing has increased sensitivity for the detection of CIN3 and CIN2 after a single screening round. As compared with Pap testing, HPV testing has greater sensitivity for detection of cervical intraepithelial neoplasia. 9 HPV testing alone for primary screening appears promising in women aged 30 years and older as this group is at greatest risk of developing CIN 3.
The interval between successive smears in cervical cancer screening can be increased considerably for women with morphologically normal smears and negative for high risk oncogenic types. Strictly following up the women who are positive for high risk oncogenic types and testing women negative for HPV at longer intervals could be an effective strategy for cervical cancer screening. The only limitation in the implementation of HPV testing in cervical cancer screening is the cost factor considering low resource setting like our country.
